Levelling Up series Part 1: Time to level up testing and treatment
Peter Keeling
At Diaceutics we maintain the view that better testing is critical in delivering better patient outcomes, and when aligned with targeted therapy, the two are transformative.
A recent Irish Times summary highlighting a new report from the Irish National Cancer Registry supports the first part of the below statement, and of course the continued increase of precision medicine test-treatment combinations supports the second.
“Early diagnosis is leading to better cancer outcomes, including near-total survival at five years for some forms of the disease, according to a new report from the National Cancer Registry (NCRI). A high proportion of cancers affecting the skin (melanoma), uterus and prostate present at an early stage, resulting in five-year survival of “up to 100 per cent”, according to the NCRI annual statistical report.”
- The Irish Times
So, what’s the problem? Simply this; Precision medicine will remain curtailed as a force for patient good by the inequalities of market reward and published outcome evidence between testing and treatment. For many in clinical and lab practice there is no surprise that better testing of patients has the potential to radically alter their life, yet newspapers present this fact as revelatory.
At Diaceutics we ask ourselves a different set of questions:
-
What is the right level of clinical risk/reward for better testing? (It is surely not the current 3% of all the monies currently spent in healthcare!)
-
What are the disruptive business models of tomorrow which will reintegrate testing and treatment at a system level? (It is surely not the current model where 65% of patients are denied access to precision medicine because of inattention to the diagnostic and treatment pathway and 30% of precision medicines fail to deliver an ROI as a consequence.)
-
Is it time to let “patients” take control of their own diagnostic pathway? (After all, decades of minor adjustments to the market-based regime run by current incumbents has not really resulted in the democratization of the testing market.)
-
What does Standard of Care look like in the march toward the N of One and true promise of precision medicine? (We are not ready, as systems and investments are set up to cater for the mainstream).
-
How do we ensure that the multiple new innovations in diagnostic biomarkers and technology, as well as novel treatments still to come, will not stumble in added complexity? (We all recognize that regulation and reimbursement for testing and data is historically managed in silos).
If all of this seems like a wicked problem, in actuality we have never been more equipped to “level up” testing and treatment – We have greater levels of real-world data to evidence the role and value of better testing in medicine, we have labs across the globe ready to be even more proactive in rapidly supporting better treatment choices, and of course we can clearly illustrate now how every treatment choice will benefit from the clinical clarity which flows from efficient diagnostic pathways. Most of all, the broader precision medicine community is now aware of the issues above… and 50% of addressing a problem is knowing we have one.
Imagine if together we can change newspaper headlines to “better testing now the next frontier for precision medicine”.
About Diaceutics
At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome.
We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network ®
What are the key HCP engagement trends from Fierce Pharma Engage 2026?
Fierce Pharma Engage 2026 highlighted four key shifts in HCP engagement: AI as a practical enabler rather than just a buzzword, content relevance as a key differentiator, the need for connected customer journeys, and a move from activity-based to outcome-based performance measurement. Across every session, the consistent theme was that effective HCP engagement is built on behavior, data and connected experience, not reach alone.
Why is the traditional NPI list no longer enough for HCP targeting?
Traditional National Provider Identifier (NPI) list targeting is being replaced by behavior-driven segmentation that reflects an HCP's context, preferences and likelihood to act. The growing focus is on identifying the right time to activate an audience, when an HCP is most likely to engage or prescribe, rather than simply who they are or when a campaign is scheduled.
How is AI being used practically in HCP engagement today?
AI is being applied well beyond audience segmentation, supporting dynamic content personalization, next-best-action recommendations, and even augmenting field force interactions through virtual assistants like bots. This positions AI as a practical, everyday enabler across the HCP engagement ecosystem rather than a future concept.
Why does content relevance matter more than data and AI alone in HCP engagement?
With crowded inboxes and limited time, HCPs often scan rather than fully read branded content, meaning every interaction has to work harder to land. Brief, punchier subject lines and front-loaded key messages that make the call-to-action visible early tend to drive better engagement and support clearer clinical decision-making.
What does a "connected" HCP customer journey look like?
A connected HCP journey applies a Netflix-style experience to healthcare engagement, where content surfaces based on an HCP's behavior, preferences and prior interactions, rather than isolated, disconnected touchpoints. Sequence-based messaging and Next Best Action (NBA) strategies are increasingly used to create this connected, tailored experience across emails, banners and rep interactions.
How does prospective, diagnostic-data-driven engagement improve on traditional segmentation?
Written By Peter Keeling
